Current Neuro-Oncology

Volume 27 Number 34
10 December 2025

Home > Publications > Current Neuro-Oncology > Volume 27, Year 2025 > Number 34, 10 December

Byun YH, Han M, Nam SM, Hwang JH, Kim YH, Park CK, Kim MS.
Histopathologic risk factors for progression of atypical meningioma: a retrospective cohort study evaluating the impact and clinical value of mitotic count and Ki-67.
Acta Neurochir (Wien). 2025 Dec 1;167(1):303. doi: 10.1007/s00701-025-06711-4. PMID: 41324743. Observational study. ˍ

Cho WJ, Choi K, Han K, Choi SH, Yoon HI, Ahn SS, Chang JH, Kang SG, Kim SH, Lee SK, Wee CW, Park YW.
Clinical and molecular characteristics and prognostic factors of diffuse astrocytoma, IDH-wildtype, not elsewhere classified.
J Neurooncol. 2025 Dec 1;176(1):103. doi: 10.1007/s11060-025-05358-6. PMID: 41324809. Observational study˰ ˍ

Colman H, Lombardi G, Wong ET, Walbert T, Eoli M, Lassman AB, Peereboom DM, Kizilbash SH, Kamiya-Matsuoka C, Pitz MW, Strowd RE, Desjardins A, Kumthekar P, Mason W, Pellerino A, Soffietti R, Butowski N, Forsyth PA, Hamza MA, Hau P, Lallana E, Nabors B, Piccioni D, Uhlmann EJ, Welsh LC, Wen PY, Dietrich J, Wang C, Levin VA.
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.
J Clin Oncol. 2025 Dec 1:JCO2501204. doi: 10.1200/JCO-25-01204. PMID: 41325560. Interventional study. ˍ

Ivanidze J, Vu KV, Fu R, Brandmaier A, Szidonya L, Choudhary G, Starkey J, Wang TJ, Sisti M, McKhann LG, Puri S, Konner M, Roytman M, Lin E, Kuhn A, Osborne JR, Stieg PE, Beal K, Ramakrishna RR, Singh G, Lignelli-Dipple A, Doubrovin M, Vo AH, Welch M, Iwamoto F, Haggiagi A, Donovan L, Diaz M, Gill B, Liechty B, Pisapia DJ, Walker J, Magge RS, Wood M, Corzo VM, Sanusi OR, Raslan A, Dogan A, Bowden S, Nehmeh SA, Nickerson J, Mallak N, Ruiz A, Ambady P, Nabavizadeh A, Barajas RF Jr.
Clinical Utility of [F18]-Fluciclovine PET/MRI for Differentiating True Progression from Treatment-Related Changes in Patients with Glioblastoma.
AJNR Am J Neuroradiol. 2025 Dec 1:ajnr.A9120. doi: 10.3174/ajnr.A9120. PMID: 41326230. Observational study. ˍ

Zhang J, Wang P, Ren Y, Chen L, Feng J, Liu F, Deng K, Bao Z, Qiu X, Liu Y.
Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial.
Cancer. 2025 Dec 1;131(23):e70171. doi: 10.1002/cncr.70171. PMID: 41328764. Interventional study. ˍ

Liu JKC, Tran N, Piteo C, Peinhardt A, Vogelbaum MA.
Results of a Pilot Trial of Infusion Rate Escalation During Convection Enhanced Delivery of Topotecan with a Multiport Catheter.
World Neurosurg. 2025 Dec 2:124696. doi: 10.1016/j.wneu.2025.124696. PMID: 41344399. Interventional study. ˍ

Husar E, Simon S, Abdolzade-Bavil A, Augustin A, Eigenmann MJ, Freimoser-Grundschober A, Gavrilov A, Gianotti R, Gjorevski N, Godoy P, Hollenstein A, Lechmann M, Nicolini VG, Polonchuk L, Stokar-Regenscheit N, Villaseñor R, Wagner C, Waldhauer I, Walz AC.
An alternative nonclinical approach to support the first-in-human clinical trial of a T-cell bispecific targeting EGFRvIII.
J Pharm Sci. 2025 Dec 4:104112. doi: 10.1016/j.xphs.2025.104112. PMID: 41352482. Translational study˰ ˍ

Kennemer AA, Gordillo AJ, Shah VS, Zhou X.
Risk of brain tumors following traumatic brain injury: A retrospective cohort study.
Neurosurg Rev. 2025 Dec 4;49(1):46. doi: 10.1007/s10143-025-03972-6. PMID: 41340002. Observational study˰ ˍ

Lin LY, Lee HJ, Wu CH, Wu HW, Wu CC, Yu KW, Chen YW, Lee YY, Chen HH, Wu JC, Tai WA, Lin TM, Chang FC.
Clinical and MR findings for the diagnosis of recurrent tumors versus radiation-induced secondary tumors of malignant pediatric brain tumors of the posterior fossa.
World Neurosurg. 2025 Dec 4:124706. doi: 10.1016/j.wneu.2025.124706. PMID: 41352681. Observational study. ˍ

Mittra ES, Solnes LB, van der Veldt AAM, Wong J, Aloj L, Heinrich MC, Chen CT, Rowe SP, Brabander T, Pacey S, Aimone P, Pathak D, Blumenstein L, Liu Y, Iagaru A.
Phase 1 Study of [¹⁷⁷Lu]Lu-NeoB in Patients with Advanced Solid Tumors Overexpressing Gastrin-Releasing Peptide Receptor: Preliminary Safety and Dosimetry Results.
J Nucl Med. 2025 Dec 4:jnumed.125.270411. doi: 10.2967/jnumed.125.270411. PMID: 41344852. Interventional study. ˍ

Sirirungreung A, Lee PC, Hu YH, Liew Z, Federman N, Ritz B, Heck JE.
Exposure to acetaminophen (paracetamol) during pregnancy and childhood cancer: a population-based cohort study in Taiwan.
Cancer Epidemiol Biomarkers Prev. 2025 Dec 4. doi: 10.1158/1055-9965.EPI-25-1034. PMID: 41342591. Observational study˰ ˍ

Stadlbauer A, Nikolic K, Marhold F, Doerfler A, Kinfe TM, Meyer-Bäse A, Schnell O, Ökrösi A, Heinz G, Oberndorfer S.
Microvascular Perfusion MRI Improves Therapy Monitoring and Detects Early Recurrences of Gliomas: A Large-Scale Trial of 2000 Follow-Up Examinations.
AJNR Am J Neuroradiol. 2025 Dec 4;46(12):2561-2569. doi: 10.3174/ajnr.A8922. PMID: 41344846. Observational study. ˍ

Vaz-Salgado MÁ, Del Barco S, Sepúlveda JM, Alonso M, Pineda E, Balana C, Martínez-García M, Gironés R.
Glasdegib in combination with temozolomide and radiotherapy in adult patients with newly diagnosed glioblastoma: the phase Ib/II GEINO 1602 trial.
Nat Commun. 2025 Dec 4. doi: 10.1038/s41467-025-66747-z. PMID: 41345097. Interventional study. ˍ

Mahé I, Chapelle C, Girard P, Carrier M, Palomares LJ, Samama CM, Helfer H, Gerotziafas G, Laporte S, Vicaut E, Mismetti P; API-CAT Study Group; API-CAT Investigators.
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial.
Lancet Haematol. 2025 Dec 6:S2352-3026(25)00291-1. doi: 10.1016/S2352-3026(25)00291-1. PMID: 41365312. Interventional study˰ ˍ

Chang SM.
Our collective responsibility to address challenges facing research integrity in Neuro-Oncology.
Neuro Oncol. 2025 Dec 8:noaf278. doi: 10.1093/neuonc/noaf278. PMID: 41359773. Editorial˰ ˍ

Wang Y, Wang C, Yin S, Yu C, Li X, Kang X, Yang S, Xie W, Lin Y, Wu Z, Li W, Chen F.
Phase 2 Trial of PD-1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma.
CNS Neurosci Ther. 2025 Dec 8;31(12):e70659. doi: 10.1111/cns.70659. PMID: 41358608. Interventional study. ˍ

Santos MDC, Rodrigues NMV, Gibram F, Brunelli J, Campos ACP, Mancini A, Feher O, Marta GN, Hanna SA, Chung C, Moraes FY, Maldaun MVC.
Wallerian degeneration of the corticospinal tract following multimodal high-grade glioma treatment: a case series and recommendations for radiotherapy planning.
Front Oncol. 2025 Nov 14;15:1605190. doi: 10.3389/fonc.2025.1605190. PMID: 41323381. Observational study. ˍ

Aprile M, Di Nunno V, Gatto L, Tosoni A, Balestrini D, Ramponi V, Conti A, Maffei M, Battaglia S, Argento CM, Zuliani E, Bartolini S, Margotti M, Gentilini F, Tallini G, Asioli S, Franceschi E.
How to predict progression-free survival in patients with grade 2 IDH-mutated diffuse gliomas after surgery: a long-term follow-up analysis.
Front Oncol. 2025 Nov 18;15:1673285. doi: 10.3389/fonc.2025.1673285. PMID: 41341389. Observational study. ˍ

Liu S, Liang R.
Risk stratification for intracranial infection after high-grade gliomas surgery: a nomogram development and validation study.
Front Oncol. 2025 Nov 19;15:1697966. doi: 10.3389/fonc.2025.1697966. PMID: 41347088. Observational study. ˍ

Chandan Reddy S, Mao T, Gendreau J, Ahmed AK, Mukherjee D.
Clinical predictors of overall survival in elderly oligodendroglioma patients: A Surveillance, Epidemiology, and End Results (SEER) database analysis.
Clin Neurol Neurosurg. 2025 Nov 27;261:109279. doi: 10.1016/j.clineuro.2025.109279. PMID: 41319580. Observational study˰ ˍ

Zhang J, Gan T, Qiao W, Luo C, Xie X, Yao Y.
Predicting short-term recurrence and identifying key risk factors in elderly glioma patients: Insights from a retrospective cohort study.
Clin Neurol Neurosurg. 2025 Nov 27;261:109275. doi: 10.1016/j.clineuro.2025.109275. PMID: 41319581. Observational study˰ ˍ